Novo Nordisk's first-quarter print, formally on the U.S. tape Thursday and now extending into Friday's IQVIA window, recorded what the company's chief executive Mike Doustdar called "a record-breaking start" for the Wegovy pill. [1] More than two million prescriptions have been written since the January 5 launch, against more than one million patients now on therapy, with 80 percent new to GLP-1 treatment. [1] [2] First-quarter pill sales reached 2.26 billion Danish kroner — about $354 million — almost double the analyst consensus of 1.16 billion kroner. [3] [4] Eli Lilly's Foundayo, the orforglipron pill that won FDA approval April 1 and shipped April 9, prescribed 5,612 times in its third week against the Wegovy pill's 134,000 the same week, prints its fourth-week IQVIA fills into the same window today or Saturday — the first numerically falsifiable test of RBC Capital Markets analyst Trung Huynh's bar that Foundayo must reach more than 90,000 weekly prescriptions by week 12 to keep the $1.4-billion full-year model on track. [5]

The paper's Wednesday read on the eighty-percent naive share called the only-pill window closed, the volume real, and the patient cohort mostly new to therapy. The Tuesday brief on Foundayo's week-four watch against the 90,000-script week-twelve bar named Friday's print as the binary against which the model can be marked. What the day adds is the receipt: Novo has crossed two million scripts on the same calendar day Foundayo's fourth-week chart prints into a 24-to-1 ratio that either compresses or holds.

The arithmetic is uncomfortable for Lilly. To reach 90,000 weekly fills by week 12, Foundayo would need to roughly double its weekly run-rate every two weeks for eight weeks — an exponential ramp with no historical analog in oral GLP-1 launches. [5] [6] Wegovy oral cleared 18,410 prescriptions in its first full week, scaled to 113,000 by week 13 and 207,000 by April 17. [7] Foundayo's reported trajectory — 1,390 in week one, 3,707 in week two, 5,612 in week three — implies roughly 7,500 to 9,000 in week four if linear growth holds, against the 90,000-by-week-twelve milestone Huynh has named in the open. [5] [6] Lilly's own briefing material says more than 20,000 patients have been treated, that 8,000 prescribers have written the drug, and that more than 1,000 patients are starting Foundayo per day — a number that, if sustained for the full week, implies roughly 7,000 weekly fills. [8] CEO Dave Ricks told CNBC last week that "this is going to play out over quarters, not days." [8] The chart is going to play out today.

Underneath Novo's record print is a price number that does the actual work. The Wegovy-pill starting dose, 1.5 milligrams, costs $149 a month at retail; the 4-milligram dose costs the same through August 31, then rises to $199; the 9-milligram and 25-milligram doses run $299. Roughly 450,000 of the 1.3 million Q1 fills were the $149 starter dose, by BMO Capital Markets analysts' read, which flagged that revenue at about $355 million for the quarter came in around 12 percent below the roughly $1-billion revenue line some sell-side desks had carried into the print. [3] Volume real, dollars compressed: the same launch that beat the analyst-tracked pill-revenue line by 95 percent on volume undershot the broader top-of-funnel revenue expectation. Novo raised its full-year guidance from a constant-currency revenue decline of 5 to 13 percent to a decline of 4 to 12 percent — a one-point widening of the upper bound and a two-point lift of the floor. [3] Doustdar called the $149 tier a "sweet spot." It is also a structural commitment: half of U.S. Wegovy revenue now comes through self-pay, up from "just over 10 percent a year ago." [3]

The 80-percent naive-share figure means most of the people now starting therapy are not switching from Zepbound or Ozempic; they are starting from the place a hundred million Americans have been sitting for years. [9] The clinical literature on obesity treatment has, for a decade, divided populations into "treated" and "untreated"; what the Q1 print discloses is that the untreated cohort is, in volume, willing to pay $149 a month for a daily tablet that requires waiting half an hour before breakfast. The injectable Wegovy class, before the pill, had reached perhaps three million of the roughly 100 million Americans who meet CDC criteria for obesity or weight-related illness — fewer than three percent. The pill is now adding roughly 200,000 new starts a week, almost all of them, by the company's own count, to people who had not previously been on therapy. The patient cohort the company has been chasing for fifteen years has, in three months, started showing up at the pharmacy counter.

Lilly's framing of the Foundayo cohort matches Novo's. Ricks told CNBC that more than 80 percent of people taking Foundayo are also new to GLP-1s. [8] The market is not a zero-sum exchange between two pills. It is a single expansion in which both companies are reaching the same untreated population, on different scales, through different channels. Wegovy carries TrumpRx self-pay coverage at announced $25 and $149 tiers; Foundayo had not appeared on the federal portal as of last week. [10] Two of the three largest pharmacy benefit managers have commercial coverage in place for Foundayo; the third has not. Foundayo's structural drag is that it requires no fasting window and can be taken any time of day, but its launch architecture — LillyDirect plus Amazon Pharmacy as the priority channel, a $149-to-$299 self-pay grid, prior-authorization paperwork that takes 3-7 days for most commercial plans — extends the conversion runway that Wegovy's January launch front-loaded. [10]

The mental-health signal sitting beside the prescription chart deserves a paragraph on its own. The Lancet Psychiatry's 95,490-individual within-person Swedish cohort study published in early May associated semaglutide with adjusted hazard ratios of 0.58 for worsening mental illness, 0.56 for worsening depression, 0.62 for anxiety, 0.53 for substance-use disorder, and 0.56 for self-harm. [11] A contemporaneous comparator-class study on ScienceDirect found the opposite directional signal — semaglutide associated with elevated psychiatric risk versus SGLT2 inhibitors and DPP4 inhibitors as the comparator pool, rather than versus periods when patients were not on GLP-1 therapy. The two designs answer different questions, and they answer them in opposite directions. The FDA approved the Wegovy pill December 22, 2025 with the same boxed warning the injection carries. The post-marketing surveillance pool, with more than one million patients now on therapy, is large enough to detect rare adverse events; it is also large enough to detect rare benefits. What it is not yet large enough to do is settle the labeling question Novo's Q1 print just made urgent.

The injection portfolio is a footnote in the volume story but a structural one in the dollar story. Wegovy injection sales rose 12 percent year-on-year to 18.2 billion kroner in the quarter — slightly below LSEG expectations. [3] Novo launched the higher-dose Wegovy HD (semaglutide 7.2 milligrams) in April; the STEP UP trial showed 20.7 percent mean weight loss, comparable to Lilly's Zepbound. [3] CFO Karsten Munk Knudsen told reporters Novo is not seeing significant patient drop-offs from injection to pill. The pricing architecture is doing the work: the company has deliberately put the pill below the injection at retail, which means the pill is not cannibalizing the shot; it is reaching patients who were not in the room. The 10,000-person franchise headcount reduction Novo has been executing inside the same twelve months sits beside the volume as the structural cost of building the new launch model — the obesity-medicine portfolio is now organized around two formulations, two price points, and two distribution channels (telehealth and retail) that did not exist together a year ago.

The structural reading of the 80-percent naive number is the demographic-winter receipt. The paper has been writing the demographic-winter thread as a fertility-and-aging register tied to body-composition science the obesity literature has accumulated over fifteen years. What the Q1 print converts the thread into is an operating one. The volume is now real enough to be a population-health variable; the naive share is high enough that this is mostly net new GLP-1 demand, not switching; and the price tier is low enough that the population effect is happening in households, not benefit plans. Half of U.S. Wegovy revenue now bypasses the PBM architecture entirely. Express Scripts, Caremark, and OptumRx have built their negotiating leverage on covered-life concentration; a self-pay-dominant market is one where the PBM is the cost-of-entry, not the gatekeeper. Industry attorneys have warned the channel shift will eventually trigger a DOJ or FTC inquiry into rebate structures. None has surfaced.

Two calendar markers compress the next 14 days. Foundayo's week-four IQVIA print arrives Friday or Saturday into the same U.S. tape that has just paid Novo a +6.7-percent close in Copenhagen and a guidance raise. [3] If Lilly's print holds at or below the week-three baseline of 5,612, the 24-to-1 ratio extends and Huynh's $1.4-billion FY model is in trouble; if it steps materially toward 12,000 or higher, the gap is compressing. [5] [6] Either way, the model is now marked against an externally announced milestone. Novo has filed for European approval of the pill with the EMA and other regulators, with launches expected in the second half of 2026 into a single-payer system where self-pay rates are lower and the demographic curve is older. The U.S. launch is the dress rehearsal for a market the European obesity literature has been calling "untreated" for the same two decades.

The clinical implication of the 80-percent naive share deserves a closing sentence on its own terms. When most of the people starting GLP-1 therapy in any given week are doing it for the first time, the medicine's population-level effects — body composition, blood pressure, fertility, mental health, addiction — start landing on cohorts the literature has not previously observed at scale. The 1.3 million Q1 prescriptions and the one million patients on therapy mean the questions the GLP-1 literature has been asking in journal articles are now being answered in pharmacy data. Volume real. Dollars compressed. Patients mostly new. What the August call will disclose is whether the maintenance-dose conversion rate from the $149 starter holds at any disclosed level — that conversion is the unannounced variable on which Novo's full-year revenue line will turn. The pill that arrived in January as a launch is, on Friday, an operating fact about how 100 million Americans are about to be touched by the same molecule, and a numerical bar in Indianapolis that Lilly has 11 weeks to reach.

-- NORA WHITFIELD, Chicago